ArticleScience (New York, N.Y.)2018
MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A.
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers.
0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
163 citing papers in PubMed, 246 citations in OpenAlex.
- Mitofusin Activation Delays Aging inCells · 2026Article
- SIRT3-mediated DRP1 acetylation changes are associated with the restoration of mitochondrial function and alleviation of anterior cruciate ligament injury-induced osteoarthritis.Journal of molecular histology · 2026Article
- HDAC6 inhibition alleviates mitochondrial trafficking in models of Charcot-Marie-Tooth disease type 2A.JCI insight · 2026Article
- Neuromuscular Dysfunction and Charcot-Marie-Tooth Disease Reversal in Mfn2 T105M Knock-In Rats.International journal of molecular sciences · 2026Article
- Mitochondrial quality control in health and disease: mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Mitochondrial-endoplasmic reticulum interactions in lung diseases.Cell death & disease · 2026Review
- Disruption of ER-mitochondria contact sites by coronavirus replication organelles sustains viral replication via NSP3 stabilization.The EMBO journal · 2026Article
- [Deubiquitinase USP30 alleviates brain injury after intracerebral hemorrhage by regulating MFN2 ubiquitination].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
- Disease-causing MFN2 mutants impair mitochondrial fission dynamics by distinct DRP1 dysregulation.Cell death & disease · 2026Article
- Investigating the role of serum NfL, FGF21, NCAM1 and GDF15 as disease biomarkers for Charcot-Marie-Tooth type 2A.Scientific reports · 2026Article
- Hereditary Polyneuropathies in the Era of Precision Medicine: Genetic Complexity and Emerging Strategies.Genes · 2026Review
- Mitochondria in the middle of inter- organellar cross talk: insights from yeast to humans.Frontiers in cell and developmental biology · 2026Review
- Advances and challenges in modeling Charcot-Marie-Tooth type 2A using iPSC-derived models.Stem cell reports · 2025Review
- Drug repurposing screen identifies an HRI activating compound that promotes adaptive mitochondrial remodeling in MFN2-deficient cells.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Elevated Acetylation of MFN2 is Accompanied by the Disruption of Mitochondrial Energy Metabolism and Inflammation in a Mouse Model of Depression.Molecular neurobiology · 2025Article
- Mitofusin agonists enhances long-term engraftment and potency of HSC culturesbioRxiv : the preprint server for biology · 2025Article
- Charcot-Marie-Tooth type 2A variants of mitofusin 2 sensitize cells to apoptotic cell death.Journal of cell science · 2025Article
- Unlocking a Nano-Aluminum Oxide Lewis Acid Layer as the Electrocatalyst for Hydrogenation of Thiophene and Other Arenes.Journal of the American Chemical Society · 2025Article
- Therapies for Mitochondrial Disease: Past, Present, and Future.Journal of inherited metabolic disease · 2025Review
- Drug Repurposing Screen Identifies an HRI Activating Compound that Promotes Adaptive Mitochondrial Remodeling in MFN2-deficient Cells.bioRxiv : the preprint server for biology · 2025Article
103 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Agostinho G RochaDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-7134-7376
Antonietta FrancoDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-5487-1800
Andrzej M KrezelDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0003-3246-5008
Jeanne M RumseyDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Justin M AlbertiDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
William C KnightDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Nikolaos BirisDepartments of Biochemistry and Medicine, Wilf Family Cardiovascular Research Institute, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0003-4055-5521
Emmanouil ZacharioudakisDepartments of Biochemistry and Medicine, Wilf Family Cardiovascular Research Institute, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA.
James W JanetkaDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-9888-5411
Robert H BalohDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-0100-8376
Richard N KitsisDepartments of Medicine and Cell Biology, Wilf Family Cardiovascular Research Institute, Albert Einstein Cancer Center, and Einstein-Mount Sinai Diabetes Research Center, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0003-1395-9694
Daria Mochly-RosenDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-6691-8733
R Reid TownsendDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Evripidis GavathiotisDepartments of Biochemistry and Medicine, Wilf Family Cardiovascular Research Institute, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0001-6319-8331
Gerald W DornDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA. gdorn@wustl.edu.
Washington University in St. Louis · USAlbert Einstein College of Medicine · USCedars-Sinai Medical Center · USStanford University · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MWORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2MWU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8MWashington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4MTrainingP41GM103422 · NIGMS · WASHINGTON UNIVERSITY · PI YARASHESKI, KEVIN E · 2012 to 2019
$12.0MTHE MITOCHONDRIAL DYNAMISM/FITNESS/BIOGENESIS INTERACTOME IN CARDIAC DISEASER35HL135736 · NHLBI · WASHINGTON UNIVERSITY · PI DORN, GERALD W. · 2017 to 2023
$6.4MSmall Molecule Activators of Pro-apoptotic BAX for Cancer TherapyR01CA178394 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI GAVATHIOTIS, EVRIPIDIS · 2014 to 2024
$3.7MLinking cell death and mitochondrial quality control mechanisms in heart diseaseR01HL128071 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI DORN, GERALD W., KITSIS, RICHARD N · 2015 to 2018
$2.1MNCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR002345NCI NIH HHS P30 CA013330NCI NIH HHS R01 CA178394NHLBI NIH HHS R01 HL128071NHLBI NIH HHS R35 HL135736NIGMS NIH HHS P41 GM103422
Abstract
Mitofusins (MFNs) promote fusion-mediated mitochondrial content exchange and subcellular trafficking. Mutations in
Indexed as
Drug DesignAmino Acid SubstitutionAnimalsArginineAxonsCharcot-Marie-Tooth DiseaseDisease Models, AnimalGlutamineGTP PhosphohydrolasesHumansMethionineMiceMice, Inbred C57BLMitochondriaMitochondrial DiseasesMitochondrial ProteinsArginineGlutamineGTP PhosphohydrolasesMethionineMFN2 protein, humanMfn2 protein, mouseMitochondrial ProteinsOligopeptidesProtein KinasesPTEN-Induced Putative KinaseSmall Molecule LibrariesThreonine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.